Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

pembrolizumab 29Cisplatin 18Nivolumab 14Carboplatin 14Paclitaxel 13Cyclophosphamide 13Radiation 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Magnetic Resonance Spectroscopy 9Cytarabine 9Vincristine 8Radiosurgery 8Docetaxel 8Bevacizumab 8Pemetrexed 7Metformin 7Leucovorin 7Injections 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Letrozole 6Irinotecan 6Ipilimumab 6Gemcitabine 6Dexamethasone 6venetoclax 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡